Cart
sales@molnova.com
NTNCB hydrochloride
CAS No. 191931-56-3
NTNCB hydrochloride( —— )
Catalog No. M27672 CAS No. 191931-56-3
NTNCB hydrochloride is an antagonist of neuropeptide Y (NPY) Y5 receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 65 | In Stock |
|
| 10MG | 103 | In Stock |
|
| 25MG | 211 | In Stock |
|
| 50MG | 334 | In Stock |
|
| 100MG | 538 | In Stock |
|
| 200MG | 768 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNTNCB hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionNTNCB hydrochloride is an antagonist of neuropeptide Y (NPY) Y5 receptor.
-
DescriptionNTNCB hydrochloride is an antagonist of neuropeptide Y (NPY) Y5 receptor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptorutrophin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number191931-56-3
-
Formula Weight508.07
-
Molecular FormulaC25H34ClN3O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (246.03 mM)
-
SMILESCl.[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PF-00835231
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.
-
CADD522
CADD522 is a potent inhibitor of runt-related transcription factor-2 (RUNX2)-DNA binding with an IC50 of 10 nM, with antitumor activityCADD522 is a potent inhibitor of runt-related transcription factor-2 (RUNX2)-DNA binding( IC50 of 10 nM), has antitumor activity.
-
TT-10
TT-10 (TAZ-K), an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity, has potential application in heart disease research, specifically for conditions characterized by loss of cardiomyocytes.
